Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab

Floaters or visual disturbance in a patient with ENKL should prompt evaluation for possible vitreoretinal involvement. Lymphoma with ocular involvement should be treated aggressively and in most cases heralds CNS involvement.

Detalles Bibliográficos
Autores principales: Mallal, Peter, Ammanuel, Benhur, White, Rohen, Kennedy, Chris, Cheah, Chan Yoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133067/
https://www.ncbi.nlm.nih.gov/pubmed/34026185
http://dx.doi.org/10.1002/ccr3.4194
_version_ 1783695012688560128
author Mallal, Peter
Ammanuel, Benhur
White, Rohen
Kennedy, Chris
Cheah, Chan Yoon
author_facet Mallal, Peter
Ammanuel, Benhur
White, Rohen
Kennedy, Chris
Cheah, Chan Yoon
author_sort Mallal, Peter
collection PubMed
description Floaters or visual disturbance in a patient with ENKL should prompt evaluation for possible vitreoretinal involvement. Lymphoma with ocular involvement should be treated aggressively and in most cases heralds CNS involvement.
format Online
Article
Text
id pubmed-8133067
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81330672021-05-21 Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab Mallal, Peter Ammanuel, Benhur White, Rohen Kennedy, Chris Cheah, Chan Yoon Clin Case Rep Case Reports Floaters or visual disturbance in a patient with ENKL should prompt evaluation for possible vitreoretinal involvement. Lymphoma with ocular involvement should be treated aggressively and in most cases heralds CNS involvement. John Wiley and Sons Inc. 2021-05-19 /pmc/articles/PMC8133067/ /pubmed/34026185 http://dx.doi.org/10.1002/ccr3.4194 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Mallal, Peter
Ammanuel, Benhur
White, Rohen
Kennedy, Chris
Cheah, Chan Yoon
Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
title Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
title_full Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
title_fullStr Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
title_full_unstemmed Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
title_short Simultaneous intraocular and cutaneous extranodal NK/T‐cell lymphoma refractory to multiple therapies including pembrolizumab
title_sort simultaneous intraocular and cutaneous extranodal nk/t‐cell lymphoma refractory to multiple therapies including pembrolizumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133067/
https://www.ncbi.nlm.nih.gov/pubmed/34026185
http://dx.doi.org/10.1002/ccr3.4194
work_keys_str_mv AT mallalpeter simultaneousintraocularandcutaneousextranodalnktcelllymphomarefractorytomultipletherapiesincludingpembrolizumab
AT ammanuelbenhur simultaneousintraocularandcutaneousextranodalnktcelllymphomarefractorytomultipletherapiesincludingpembrolizumab
AT whiterohen simultaneousintraocularandcutaneousextranodalnktcelllymphomarefractorytomultipletherapiesincludingpembrolizumab
AT kennedychris simultaneousintraocularandcutaneousextranodalnktcelllymphomarefractorytomultipletherapiesincludingpembrolizumab
AT cheahchanyoon simultaneousintraocularandcutaneousextranodalnktcelllymphomarefractorytomultipletherapiesincludingpembrolizumab

Ejemplares similares